Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) — The “Patient Derived Xenograft (PDX) Models Market Report 2024” report has been added to ResearchAndMarkets.com’s offering.
The patient derived xenograft (PDX) models market is anticipated to expand significantly, from $0.35 billion in 2023 to $0.4 billion in 2024, according to recent data. This market demonstrates a robust compound annual growth rate (CAGR) of 16%, and is projected to continue this growth trajectory, potentially reaching a valuation of $0.74 billion by 2028 at a CAGR of 16.1%.
This upsurge is largely driven by an increased focus on personalized medicine, a growing need for humanized PDX models, and a rise in global cancer incidence. Moreover, the market is buoyed by advancing technology in precision oncology, alongside amplified research and development funding for cancer treatment innovations.
Growth Factors and Industry Trends
The surge of personalized healthcare, which holds the promise of tailoring treatments to individual patient profiles, is a significant factor fueling market expansion. PDX models stand at the forefront of personalized medicine, propelling the demand for humanized PDX models which closely emulate human tumor biology. One pertinent example is the February 2024 report by the Personalized Medicine Coalition (PMC), which highlighted the FDA’s approval of an increased number of personalized treatments, emphasizing the industry’s commitment to innovative and effective healthcare solutions.
Pioneering efforts by key market players continue to reshape the landscape with technological advancements. Notably, there have been notable strides in the development of PDX models, incorporating cutting-edge in vivo bioluminescence imaging to monitor tumor development and response to treatment in real-time. This has significant implications for drug development sectors, particularly in facilitating individualized therapeutic strategies and enhancing the precision of preclinical research.
Market Landscape and Acquisition Movements
The market landscape for PDX models remains dynamic with strategic partnerships and acquisitions, such as Inotiv Inc.’s acquisition of Envigo RMS Holding Corp., which culminated in a transaction valued at $271 million. With this move, the consolidation aims to optimize research model availability, streamline service delivery, and enhance overall operational efficacy within the industry. The competitive framework of the PDX models market comprises leading entities such as Laboratory Corporation of America Holdings, WuXi AppTec Co. Ltd., and Charles River Laboratories International Inc., to name a few. These organizations are noteworthy for their commitment to pioneering research and delivery of high-quality models and services across the biomedical landscape.
Geographical Insights
Geographically, North America emerged as the paramount region in the PDX models market space in 2023. However, the Asia-Pacific region is anticipated to experience the most rapid growth within the forecast period. The comprehensive market report canvasses an array of regions and nations, delving into their individual contributions and trajectories within the global sphere of patient derived xenograft (PDX) models.
Applications and Use-Cases
PDX models, characterized by the transplantation of human tumors into immunodeficient animal hosts, stand as a cornerstone for investigating tumor biology and efficacy testing of novel cancer therapies prior to clinical trials. This market caters to a diverse range of applications, notably preclinical drug development, precision medicine, and basic cancer research, amongst others. It addresses the burgeoning demands of various end-user sectors including academic and research institutions, pharmaceutical enterprises, and biotechnological companies.
The ongoing evolution of the PDX models market is a clear indicator of its pivotal role in advancing oncological treatment and personalized medicine, backed by steadfast growth and innovation. The continued investment and interest in this market underscore the critical importance of PDX models in the fight against cancer and the quest for more effective therapeutic solutions.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2024 – 2028 |
| Estimated Market Value (USD) in 2024 | $0.4 Billion |
| Forecasted Market Value (USD) by 2028 | $0.74 Billion |
| Compound Annual Growth Rate | 16.1% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/wgvr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Patient Derived Xenograft (PDX) Models Market
